Inactive Instrument

Tricida, Inc.

Equities

TCDA

US89610F1012

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tricida, Inc. Went Out of Business CI
First Motion for Exclusivity Period Extension Approved For Tricida, Inc. CI
Fifth Amended Liquidation Plan Approved for Tricida, Inc. CI
Fifth Amended Liquidation Plan Filed by Tricida, Inc. CI
Fourth Amended Liquidation Plan Filed by Tricida, Inc. CI
First Motion for Exclusivity Period Extension Filed by Tricida, Inc. CI
North American Morning Briefing : China Data Helps -3- DJ
North American Morning Briefing : Stock Futures -3- DJ
Fourth Amended Disclosure Statement Approved for Tricida, Inc. CI
Fourth Amended Disclosure Statement Filed by Tricida, Inc. CI
Third Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc. CI
Second Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc. CI
First Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc. CI
Motion for Asset Sale Approved for Tricida, Inc. CI
Motion for Asset Sale Approved for Tricida, Inc. CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc. CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc. CI
Tricida, Inc. Announces Resignation of David Bonita as Director CI
Bidding Procedure Approved for Tricida, Inc. CI
Tricida, Inc.(OTCPK:TCDA.Q) dropped from NASDAQ Composite Index CI
Top Premarket Gainers MT
Tricida, Inc.(NasdaqGS:TCDA) dropped from S&P TMI Index CI
Liquidation Plan and Disclosure Statement Filed by Tricida, Inc. CI
Tricida, Inc. Filed for Bankruptcy CI
Motion for Asset Sale Filed by Tricida, Inc. CI
Chart Tricida, Inc.
More charts
Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.
More about the company
  1. Stock
  2. Equities
  3. Stock Tricida, Inc. - OTC Markets
  4. News Tricida, Inc.
  5. Goldman Sachs Adjusts Tricida Price Target to $22 From $25, Maintains Buy Rating